Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 3/20 | 0.52 |
| ▸ | HTR2A | P28223 | 4/20 | 0.47 |
| ▸ | DRD3 | P35462 | 1/20 | 0.47 |
| ▸ | HTR2C | P28335 | 2/20 | 0.46 |
| ▸ | DRD2 | P14416 | 4/20 | 0.44 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.44 |
| ▸ | HTR1A | P08908 | 2/20 | 0.44 |
| ▸ | ACHE | P22303 | 2/20 | 0.42 |
| ▸ | LCK | P06239 | 2/20 | 0.42 |
| ▸ | MAP2K1 | Q02750 | 2/20 | 0.42 |
| ▸ | CSF1R | P07333 | 1/20 | 0.42 |
| ▸ | CHRNA7 | P36544 | 2/20 | 0.41 |
| ▸ | HTR3A | P46098 | 2/20 | 0.41 |
| ▸ | SCD | O00767 | 1/20 | 0.41 |
| ▸ | HTR7 | P34969 | 1/20 | 0.39 |
| ▸ | HTR6 | P50406 | 1/20 | 0.39 |
| ▸ | GRM4 | Q14833 | 2/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23175518 | 0.89 | HTR2A (0.51) | MAPK14HTR2ADRD3DRD2SLC6A4 | |
| SCHEMBL14034032 | 0.88 | HTR2A (0.46) | MAPK14HTR2ADRD3HTR2CDRD2 | |
| Hydrochloric Acid SCHEMBL29891155 | 0.87 | HTR2A (0.45) | MAPK14HTR2ADRD3HTR2CDRD2 | |
| Hydrochloric Acid SCHEMBL23581610 | 0.87 | HTR2A (0.45) | MAPK14HTR2ADRD3HTR2CDRD2 | |
| SCHEMBL8237364 | 0.84 | MAPK14 (0.47) | MAPK14HTR2ADRD2SLC6A4ACHE | |
| SCHEMBL7966100 | 0.82 | MAPK14 (0.47) | MAPK14HTR2ADRD2SLC6A4ACHE | |
| SCHEMBL3523366 | 0.82 | MAPK14 (0.47) | MAPK14DRD2SLC6A4ACHELCK | |
| SCHEMBL1545681 | 0.82 | MAPK14 (0.47) | MAPK14HTR2ADRD3DRD2SLC6A4 | |
| SCHEMBL461287 | 0.82 | ACHE (0.61) | HTR2ADRD2SLC6A4ACHESCD | |
| SCHEMBL15487431 | 0.82 | MAPK14 (0.49) | MAPK14DRD2SLC6A4ACHELCK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2021098737-A1 | FUSED HETEROCYCLIC DERIVATIVE AND USE THEREOF | 上海枢境生物科技有限公司 | 2021-05-27 | — | — | WO | disclosed |
| US-9415047-B2 | Use of benzo five-membered nitrogen heterocyclic piperazine or piperidine derivatives | Liaoning Emmy Biological Pharmaceutical Co., Ltd. (CN) | 2016-08-16 | — | — | US | disclosed |
| US-20150297586-A1 | USE OF BENZO FIVE-MEMBERED NITROGEN HETEROCYCLIC PIPERAZINE OR PIPERIDINE DERIVATIVES | Liaoning Emmy Biological Pharmaceutical Co., Ltd. (CN) | 2015-10-22 | — | — | US | disclosed |
| EP-2924033-A1 | USE OF BENZO FIVE-MEMBERED NITROGEN HETEROCYCLIC PIPERAZINE OR PIPERIDINE DERIVATIVES | Liaoning Emmy Biological Pharmaceutical Co., Ltd (CN) | 2015-09-30 | — | — | EP | disclosed |
| CN-103830238-A | Use of benzo five-membered azaheterocyclyl piperidine derivatives | SHENYANG BEIEN PHARMACEUTICAL CO LTD | 2014-06-04 | — | — | CN | disclosed |
| CN-103833730-A | Benzo five-membered nitrogen-containing heterocycle-based piperazine derivative and preparation method as well as application thereof | LIAONING BEILEI BIOLOG PHARMACEUTICAL CO LTD | 2014-06-04 | — | — | CN | disclosed |
| US-8481729-B2 | Processes for the preparation of paliperidone | MSN LABORATORIES LIMITED (IN) | 2013-07-09 | — | — | US | disclosed |
| WO-2012032532-A1 | \"PROCESSES FOR THE PREPARATION OF 4'-[3-[4-(6-FLUORO-1,2-BENZISOXAZOL-3-YL)PIPERIDINO]PROPOXY]-3'-METHOXYACETOPHENONE AND INTERMEDIATES THEREOF\ | SYMED LABS LIMITED (IN) | 2012-03-15 | — | — | WO | disclosed |
| US-7183283-B2 | Piperidinyl-alkylamino-pyridazinone derivatives, a process for the preparation thereof and pharmaceutical compositions containing said compounds | EGIS GYOGYSZERGYAR RT. (HU) | 2007-02-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150297586-A1 | USE OF BENZO FIVE-MEMBERED NITROGEN HETEROCYCLIC PIPERAZINE OR PIPERIDINE DERIVATIVES | P2RX5, TBXA2R, CYP3A5 | MAPK14 3650/4885HTR2A 353/4885DRD3 684/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.